{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:59:04Z","timestamp":1786467544947,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"DOI":"10.7759\/cureus.114354","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:22:21Z","timestamp":1786465341000},"source":"Crossref","is-referenced-by-count":0,"title":["In Vivo Base Editing for Neonatal Inborn Errors of Metabolism: Clinical Progress, N-of-1 Therapy, and the Ethics of Bespoke Genetic Medicine"],"prefix":"10.7759","author":[{"given":"Oscar Mingtian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer Xia tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12100","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision","volume":"42","author":"H\u00e4berle J","year":"2019","unstructured":"H\u00e4berle J, Burlina A, Chakrapani A, et al.. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019, 42:1192-1230. 10.1002\/jimd.12100","journal-title":"J Inherit Metab Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.11.029","article-title":"Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency","volume":"526","author":"Choi Y","year":"2022","unstructured":"Choi Y, Oh A, Lee Y, Kim GH, Choi JH, Yoo HW, Lee BH. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022, 526:55-61. 10.1016\/j.cca.2021.11.029","journal-title":"Clin Chim Acta"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru K","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, et al.. Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med. 2025, 392:2235-2243. 10.1056\/NEJMoa2504747","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor AC","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016, 533:420-424. 10.1038\/nature17946","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli NM","year":"2017","unstructured":"Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature. 2017, 551:464-471. 10.1038\/nature24644","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru K","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al.. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021, 593:429-434. 10.1038\/s41586-021-03534-y","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone AV","year":"2020","unstructured":"Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020, 38:824-844. 10.1038\/s41587-020-0561-9","journal-title":"Nat Biotechnol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen PJ","year":"2023","unstructured":"Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023, 24:161-177. 10.1038\/s41576-022-00541-1","journal-title":"Nat Rev Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.09.002","article-title":"In\u00a0vivo somatic cell base editing and prime editing","volume":"29","author":"Newby GA","year":"2021","unstructured":"Newby GA, Liu DR. In\u00a0vivo somatic cell base editing and prime editing. Mol Ther. 2021, 29:3107-3124. 10.1016\/j.ymthe.2021.09.002","journal-title":"Mol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.140","article-title":"Genetic-based approaches to inherited metabolic liver diseases","volume":"30","author":"Zabaleta N","year":"2019","unstructured":"Zabaleta N, Hommel M, Salas D, Gonzalez-Aseguinolaza G. Genetic-based approaches to inherited metabolic liver diseases. Hum Gene Ther. 2019, 30:1190-1203. 10.1089\/hum.2019.140","journal-title":"Hum Gene Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou X","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021, 6:1078-1094. 10.1038\/s41578-021-00358-0","journal-title":"Nat Rev Mater"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA \u2014 a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA \u2014 a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0130-8","article-title":"Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia","volume":"9","author":"Baumgartner MR","year":"2014","unstructured":"Baumgartner MR, H\u00f6rster F, Dionisi-Vici C, et al.. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014, 9:130. 10.1186\/s13023-014-0130-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000422","article-title":"Methylmalonic and propionic acidemias: clinical management update","volume":"28","author":"Fraser JL","year":"2016","unstructured":"Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016, 28:682-693. 10.1097\/MOP.0000000000000422","journal-title":"Curr Opin Pediatr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek M","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012, 337:816-821. 10.1126\/science.1225829","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of\u00a0living cells","volume":"19","author":"Rees HA","year":"2018","unstructured":"Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of\u00a0living cells. Nat Rev Genet. 2018, 19:770-788. 10.1038\/s41576-018-0059-1","journal-title":"Nat Rev Genet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna JA","year":"2020","unstructured":"Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020, 578:229-236. 10.1038\/s41586-020-1978-5","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone AV","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, et al.. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019, 576:149-157. 10.1038\/s41586-019-1711-4","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-01163-8","article-title":"Engineering a precise adenine base editor with minimal bystander editing","volume":"19","author":"Chen L","year":"2023","unstructured":"Chen L, Zhang S, Xue N, et al.. Engineering a precise adenine base editor with minimal bystander editing. Nat Chem Biol. 2023, 19:101-110. 10.1038\/s41589-022-01163-8","journal-title":"Nat Chem Biol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy JM","year":"2020","unstructured":"Levy JM, Yeh WH, Pendse N, et al.. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng. 2020, 4:97-110. 10.1038\/s41551-019-0501-5","journal-title":"Nat Biomed Eng"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang JH","year":"2024","unstructured":"Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024, 9:78. 10.1038\/s41392-024-01780-w","journal-title":"Signal Transduct Target Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik's cube of human gene therapy","volume":"30","author":"Pupo A","year":"2022","unstructured":"Pupo A, Fern\u00e1ndez A, Low SH, Fran\u00e7ois A, Su\u00e1rez-Amar\u00e1n L, Samulski RJ. AAV vectors: the Rubik's cube of human gene therapy. Mol Ther. 2022, 30:3515-3541. 10.1016\/j.ymthe.2022.09.015","journal-title":"Mol Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl T","year":"2021","unstructured":"Rothgangl T, Dennis MK, Lin PJ, et al.. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021, 39:949-957. 10.1038\/s41587-021-00933-4","journal-title":"Nat Biotechnol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee RG","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC, et al.. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023, 147:242-253. 10.1161\/CIRCULATIONAHA.122.062132","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03086-7","article-title":"In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan LW","year":"2021","unstructured":"Koblan LW, Erdos MR, Wilson C, et al.. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021, 589:608-614. 10.1038\/s41586-020-03086-7","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger L","year":"2018","unstructured":"Villiger L, Grisch-Chan HM, Lindsay H, et al.. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med. 2018, 24:1519-1525. 10.1038\/s41591-018-0209-1","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-019-0357-8","article-title":"Adenine base editing in an adult mouse model of tyrosinaemia","volume":"4","author":"Song CQ","year":"2020","unstructured":"Song CQ, Jiang T, Richter M, et al.. Adenine base editing in an adult mouse model of tyrosinaemia. Nat Biomed Eng. 2020, 4:125-130. 10.1038\/s41551-019-0357-8","journal-title":"Nat Biomed Eng"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xhgg.2023.100253","article-title":"A base editing strategy using mRNA-LNPs for in\u00a0vivo correction of the most frequent phenylketonuria variant","volume":"5","author":"Brooks DL","year":"2024","unstructured":"Brooks DL, Whittaker MN, Said H, et al.. A base editing strategy using mRNA-LNPs for in\u00a0vivo correction of the most frequent phenylketonuria variant. HGG Adv. 2024, 5:100253. 10.1016\/j.xhgg.2023.100253","journal-title":"HGG Adv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.11.032","article-title":"Amelioration of metabolic and behavioral defects through base editing in the Pah(R408W) phenylketonuria mouse model","author":"Yin S","year":"2025","unstructured":"Yin S, Gao L, Sun X, et al.. Amelioration of metabolic and behavioral defects through base editing in the Pah(R408W) phenylketonuria mouse model. Mol Ther. 2025, 10.1016\/j.ymthe.2024.11.032","journal-title":"Mol Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2023.10.005","article-title":"Efficient in\u00a0vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need","volume":"110","author":"Brooks DL","year":"2023","unstructured":"Brooks DL, Whittaker MN, Qu P, Musunuru K, Ahrens-Nicklas RC, Wang X. Efficient in\u00a0vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am J Hum Genet. 2023, 110:2003-2014. 10.1016\/j.ajhg.2023.10.005","journal-title":"Am J Hum Genet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.04.022","article-title":"Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases","volume":"31","author":"Zhang K","year":"2024","unstructured":"Zhang K, Wan P, Wang L, et al.. Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases. Cell Stem Cell. 2024, 31:1187-1202.e8. 10.1016\/j.stem.2024.04.022","journal-title":"Cell Stem Cell"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul H","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, et al.. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021, 384:252-260. 10.1056\/NEJMoa2031054","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore JD","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al.. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021, 385:493-502. 10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst HJ","year":"2024","unstructured":"Longhurst HJ, Lindsay K, Petersen RS, et al.. CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema. N Engl J Med. 2024, 390:432-441. 10.1056\/NEJMoa2309149","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01952-9","article-title":"A new age of precision gene therapy","volume":"403","author":"Schambach A","year":"2023","unstructured":"Schambach A, Buchholz CJ, Torres-Ruiz R, et al.. A new age of precision gene therapy. Lancet. 2023, 403:568-582. 10.1016\/S0140-6736(23)01952-9","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo E","year":"2019","unstructured":"Zuo E, Sun Y, Wei W, et al.. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science. 2019, 364:289-292. 10.1126\/science.aav9973","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald J","year":"2019","unstructured":"Gr\u00fcnewald J, Zhou R, Garcia SP, Iyer S, Lareau CA, Aryee MJ, Joung JK. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature. 2019, 569:433-437. 10.1038\/s41586-019-1161-z","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0414-6","article-title":"Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors","volume":"38","author":"Doman JL","year":"2020","unstructured":"Doman JL, Raguram A, Newby GA, Liu DR. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat Biotechnol. 2020, 38:620-628. 10.1038\/s41587-020-0414-6","journal-title":"Nat Biotechnol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-112717-094629","article-title":"Ethics of human genome editing","volume":"70","author":"Coller BS","year":"2019","unstructured":"Coller BS. Ethics of human genome editing. Annu Rev Med. 2019, 70:289-305. 10.1146\/annurev-med-112717-094629","journal-title":"Annu Rev Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.06.012","article-title":"Human germline genome editing","volume":"101","author":"Ormond KE","year":"2017","unstructured":"Ormond KE, Mortlock DP, Scholes DT, et al.. Human germline genome editing. Am J Hum Genet. 2017, 101:167-176. 10.1016\/j.ajhg.2017.06.012","journal-title":"Am J Hum Genet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim J","year":"2019","unstructured":"Kim J, Hu C, Moufawad El Achkar C, et al.. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019, 381:1644-1652. 10.1056\/NEJMoa1813279","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1911295","article-title":"Drug regulation in the era of individualized therapies","volume":"381","author":"Woodcock J","year":"2019","unstructured":"Woodcock J, Marks P. Drug regulation in the era of individualized therapies. N Engl J Med. 2019, 381:1678-1680. 10.1056\/NEJMe1911295","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing N-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives","volume":"32","author":"Synofzik M","year":"2022","unstructured":"Synofzik M, van Roon-Mom WM, Marckmann G, van Duyvenvoorde HA, Graessner H, Sch\u00fcle R, Aartsma-Rus A. Preparing N-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives. Nucleic Acid Ther. 2022, 32:83-94. 10.1089\/nat.2021.0039","journal-title":"Nucleic Acid Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/520939-in-vivo-base-editing-for-neonatal-inborn-errors-of-metabolism-clinical-progress-n-of-1-therapy-and-the-ethics-of-bespoke-genetic-medicine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:22:22Z","timestamp":1786465342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/520939-in-vivo-base-editing-for-neonatal-inborn-errors-of-metabolism-clinical-progress-n-of-1-therapy-and-the-ethics-of-bespoke-genetic-medicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.114354","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}